(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.98%) $83.03
(-1.16%) $1.619
(-0.43%) $2 337.10
(-0.58%) $27.38
(0.43%) $926.10
(-0.13%) $0.934
(-0.10%) $11.01
(-0.20%) $0.799
(0.00%) $92.17
Live Chart Being Loaded With Signals
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, manufactures, and sells bio-pharmaceutical products...
Stats | |
---|---|
Dagens volum | 17 000.00 |
Gjennomsnittsvolum | 652 400 |
Markedsverdi | 710.68M |
EPS | HKD0.0500 ( 2020-09-30 ) |
Last Dividend | HKD0.0798 ( 2023-06-05 ) |
Next Dividend | HKD0 ( N/A ) |
P/E | 19.82 |
ATR14 | HKD0.0110 (0.50%) |
FUDANZHANGJIANG Korrelasjon
10 Mest positive korrelasjoner |
---|
10 Mest negative korrelasjoner |
---|
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
FUDANZHANGJIANG Korrelasjon - Valuta/Råvare
FUDANZHANGJIANG Økonomi
Annual | 2023 |
Omsetning: | HKD850.73M |
Bruttogevinst: | HKD776.66M (91.29 %) |
EPS: | HKD0.110 |
FY | 2023 |
Omsetning: | HKD850.73M |
Bruttogevinst: | HKD776.66M (91.29 %) |
EPS: | HKD0.110 |
FY | 2022 |
Omsetning: | HKD1.03B |
Bruttogevinst: | HKD947.10M (91.85 %) |
EPS: | HKD0.130 |
FY | 2021 |
Omsetning: | HKD1.14B |
Bruttogevinst: | HKD1.06B (92.90 %) |
EPS: | HKD0.210 |
Financial Reports:
No articles found.
FUDANZHANGJIANG Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
HKD0.0859 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0.0798 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | HKD0.0623 | 2015-06-04 |
Last Dividend | HKD0.0798 | 2023-06-05 |
Next Dividend | HKD0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 9 | -- |
Total Paid Out | HKD0.566 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.49 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 2.11 | |
Div. Directional Score | 6.34 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
2377.HK | Ex Dividend Junior | 2023-06-15 | Annually | 0 | 0.00% | |
1358.HK | Ex Dividend Junior | 2023-09-29 | Annually | 0 | 0.00% | |
0400.HK | Ex Dividend Junior | 2023-06-13 | Sporadic | 0 | 0.00% | |
6699.HK | Ex Dividend Knight | 2023-07-03 | Annually | 0 | 0.00% | |
1907.HK | Ex Dividend Junior | 2023-09-08 | Semi-Annually | 0 | 0.00% | |
0939.HK | Ex Dividend Knight | 2023-07-06 | Annually | 0 | 0.00% | |
0064.HK | Ex Dividend Knight | 2023-08-29 | Semi-Annually | 0 | 0.00% | |
2886.HK | Ex Dividend Junior | 2023-05-19 | Annually | 0 | 0.00% | |
1503.HK | Ex Dividend Junior | 2023-09-13 | Semi-Annually | 0 | 0.00% | |
0553.HK | Ex Dividend Junior | 2023-07-03 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.128 | 1.500 | 7.45 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0378 | 1.200 | 8.74 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0468 | 1.500 | -0.591 | -0.886 | [0.1 - 1] |
payoutRatioTTM | 0.701 | -1.000 | 2.99 | -2.99 | [0 - 1] |
currentRatioTTM | 3.70 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 3.60 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 2.37 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.00381 | -1.500 | 9.94 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 87.71 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.0623 | 2.00 | 9.98 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | -0.0245 | 2.00 | -0.0123 | -0.0245 | [0 - 20] |
debtEquityRatioTTM | 0.00465 | -1.500 | 9.98 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.911 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0889 | 1.000 | -0.222 | -0.222 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 6.48 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.296 | 0.800 | -1.362 | -1.089 | [0.5 - 2] |
Total Score | 10.58 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 21.06 | 1.000 | 7.97 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0468 | 2.50 | -0.380 | -0.886 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.0245 | 2.00 | -0.00817 | -0.0245 | [0 - 30] |
dividendYielPercentageTTM | 3.98 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.0623 | 2.00 | 9.98 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.701 | 1.500 | 2.99 | -2.99 | [0 - 1] |
pegRatioTTM | -0.712 | 1.500 | -8.08 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0835 | 1.000 | -0.413 | 0 | [0.1 - 0.5] |
Total Score | 2.11 |
FUDANZHANGJIANG
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, manufactures, and sells bio-pharmaceutical products. It offers genetic engineering platform drugs, including CD30-DM1 antibody-drug conjugate (ADC), which is in Phase I clinical trials for tumors; Trop2-SN38 ADC that is in Phase I clinical trials for triple negative, breast, bladder, gastric, and other tumors; Trop2-BB05 ADC that is in pre-clinical studies for lung cancer and triple negative breast cancer; and HER2 ADC that has completed pre-clinical research for metastatic breast and gastric cancers. The company also provides photodynamic technical platform drugs, such as hemoporfin for port wine stain, which is in Phase IV clinical trial; and aminolevulinic acid, which is in Phase II clinical trials for cervical diseases infected by HPV and acne, as well as completed pre-clinical study for brain gliomas. In addition, it offers nano technical platform drugs, such as Nanoparticle Albumin-bound Paclitaxel that is in pre-clinical studies for tumors, as well as developing Doxorubicin liposome for tumors. Further, the company offers oral solid preparation technology, which includes obeticholic acid for hepatobiliary and autoimmune disease; timolol maleate cream that is in pre-clinical studies for infantile hemangioma; and FZJ-003 oral preparation, which is in Phase I clinical trials for rheumatoid arthritis, as well as in Phase II clinical trials for atopic dermatitis and ulcerative colitis. Additionally, it develops pharmaceutical and medical devices; medical diagnostic products and related services; and sells daily necessities, and clinical laboratory analysis instruments and software. It also engages in the technology development, transfer, consulting, and promotion activities; produces freeze-dried powder injections and APIs; and invests in overseas medical projects. The company was founded in 1996 and is based in Shanghai, the People's Republic of China.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.